ALX Oncology Holdings Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for ALX Oncology Holdings Inc. (ALXO) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income-134.85-160.81-123.48-83.46-45.74
Depreciation & Amortization0.870.840.340.740.20
Stock Based Compensation27.0926.2723.8413.915.44
Change in Working Capital-12.438.309.85-5.450.25
Change in Accounts Receivable0.000.000.000.000.54
Change in Accounts Payable-4.02-0.654.533.29-3.74
Change in Other Working Capital-8.411.521.17-7.323.46
Other Operating Activities1.791.521.1720.071.15
Net Cash from Operating Activities-121.91-130.36-89.22-68.10-38.29
Investing Activities
Capital Expenditures-0.45-1.27-1.430.67-0.03
Acquisitions0.000.000.00-4.260.00
Purchases of Investments86.70-246.63-376.790.000.00
Sales/Maturities of Investments194.11292.56142.80-4.260.00
Net Cash from Investing Activities86.2644.66-235.42-4.920.61
Financing Activities
Debt Repayment-0.83-0.39-0.39-0.280.00
Common Stock Issued1.9858.890.340.20368.56
Other Financing Activities29.66-4.40-0.660.00-3.85
Net Cash from Financing Activities30.8259.299.862.47462.88
Summary
Net Change in Cash-4.84-26.42-314.78-70.55425.20
Cash at Beginning of Period22.4748.89363.67434.229.02
Cash at End of Period17.6322.4748.89363.67434.22
Free Cash Flow-122.36-131.64-90.65-68.77-38.32
Supplemental Disclosures
Interest Paid1.391.180.100.010.43
Income Taxes Paid0.000.000.000.270.05